Background
- Enoxaparin is a LMWH used for the prophylaxis of DVT and ischemic complications of unstable angina & NSTEMI
- Also used for the treatment of VTE
- Administered as subcutaneous injection
Dosing
Thromboprophylaxis
| CrCl | Weight | |||
|---|---|---|---|---|
| <50 Kg | 50-100 Kg | 101-150 Kg | >150 Kg | |
| >30ml/min | 20mg (2000 units) OD sc | 40mg (4000 units) OD sc | 40mg (4000 units) BD sc | 60mg (6000 units) BD sc |
| 15-30ml/min | 20mg (2000 units) OD sc | 20mg (2000 units) OD sc | 40mg (4000 units) OD sc | 60mg (6000 units) OD sc |
| <15ml/min | Consultant Decision | 20mg (2000 units) OD sc | 20mg (2000 units) OD sc | Consultant Decision |
VTE (PE or DVT) management
| CrCl > 30ml/min | Enoxaparin 1.5mg/kg (150units/kg) OD sc or Enoxaparin 1mg/kg (100units/kg) BD sc The regimen should be selected by the physician based on an individual assessment including evaluation of the thromboembolic risk and of the risk of bleeding |
|---|---|
| CrCl 15-30ml/min | Enoxaparin 1mg/kg (100units/kg) OD sc |
| CrCl<15ml/min | Consultant decision |